Potential role of Renin-Angiotensin-system for tumor angiogenesis in receptor negative breast cancer

Gynecologic Oncology

Volumn 109, Issue 3, 2008, Pages 418-425

  Herr, D ^a   Rodewald, M ^a   Fraser, H M ^b   Hack, G ^a   Konrad, R ^a   Kreienberg, R ^a   Wulff, C ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Angiogenesis; Angiotensin II; Breast cancer cell; Candesartan; Inhibition

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOTENSIN II; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE; HYPOXIA INDUCIBLE FACTOR 2ALPHA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER TISSUE; CELL STRAIN MCF 7; CONTROLLED STUDY; DEVICE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VASCULARIZATION;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BENZIMIDAZOLES; BREAST NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ESTROGEN; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 44549086277     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.02.019     Document Type: Article

References (42)

1. Flamme I., Frolich T., and Risau W. Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J Cell Physiol 173 2 (1997) 206-210
2. Risau W. Mechanisms of angiogenesis. Nature 386 6626 (1997) 671-674
3. Zhang L., Hannay J.A., Liu J., Das P., Zhan M., Nguyen T., et al. Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance. Cancer Res 66 17 (2006) 8770-8778
4. Cao Y. Tumor angiogenesis and therapy. Biomed Pharmacother 59 Suppl 2 (2005) S340-S343
5. Wulff C., Wiegand S.J., Saunders P.T., Scobie G.A., and Fraser H.M. Angiogenesis during follicular development in the primate and its inhibition by treatment with truncated Flt-1-Fc (vascular endothelial growth factor Trap(A40)). Endocrinology 142 7 (2001) 3244-3254
6. Wulff C., Wilson H., Wiegand S.J., Rudge J.S., and Fraser H.M. Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2. Endocrinology 143 7 (2002) 2797-2807
7. Bernard-Marty C., Lebrun F., Awada A., and Piccart M.J. Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions. Drugs 66 12 (2006) 1577-1591
8. Timmermans P.B., Chiu A.T., Herblin W.F., Wong P.C., and Smith R.D. Angiotensin II receptor subtypes. Am J Hypertens 5 6 Pt 1 (1992) 406-410
9. Egami K., Murohara T., Shimada T., Sasaki K., Shintani S., Sugaya T., et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 112 1 (2003) 67-75
10. De Paepe B., Verstraeten V.L., De Potter C.R., Vakaet L.A., and Bullock G.R. Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma. Histochem Cell Biol 116 3 (2001) 247-254
11. Goto M., Mukoyama M., Sugawara A., Suganami T., Kasahara M., Yahata K., et al. Expression and role of angiotensin II type 2 receptor in the kidney and mesangial cells of spontaneously hypertensive rats. Hypertens Res 25 1 (2002) 125-133
12. Silvestre J.S., Tamarat R., Senbonmatsu T., Icchiki T., Ebrahimian T., Iglarz M., et al. Antiangiogenic effect of angiotensin II type 2 receptor in ischemia-induced angiogenesis in mice hindlimb. Circ Res 90 10 (2002) 1072-1079
13. Herr D., Rodewald M., Fraser H.M., Hack G., Konrad R., Kreienberg R., et al. Regulation of endothelial proliferation by the Renin-Angiotensin-System in human umbilical vein endothelial cells (2007) Reproduction 2008, in press.
14. Efrati S., Berman S., Goldfinger N., Erez N., Averbukh Z., Golik A., et al. Enhanced angiotensin II production by renal mesangium is responsible for apoptosis/proliferation of endothelial and epithelial cells in a model of malignant hypertension. J Hypertens 25 5 (2007) 1041-1052
15. Kobayashi S., Berisha B., Amselgruber W.M., Schams D., and Miyamoto A. Production and localisation of angiotensin II in the bovine early corpus luteum: a possible interaction with luteal angiogenic factors and prostaglandin F2 alpha. J Endocrinol 170 2 (2001) 369-380
16. Fernandez L.A., Twickler J., and Mead A. Neovascularization produced by angiotensin II. J Lab Clin Med 105 2 (1985) 141-145
17. Suganuma T., Ino K., Shibata K., Kajiyama H., Nagasaka T., Mizutani S., et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res 11 7 (2005) 2686-2694
18. Le Noble F.A., Hekking J.W., Van Straaten H.W., Slaaf D.W., and Struyker Boudier H.A. Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo. Eur J Pharmacol 195 2 (1991) 305-306
19. le Noble F.A., Kessels-van Wylick L.C., Hacking W.J., Slaaf D.W., oude Egbrink M.G., and Struijker-Boudier H.A. The role of angiotensin II and prostaglandins in arcade formation in a developing microvascular network. J Vasc Res 33 6 (1996) 480-488
20. Wang X.D., Chen X.M., Wang J.Z., Hong Q., Feng Z., Fu B., et al. Signal transducers and activators of transcription 3 mediates up-regulation of angiotensin II-induced tissue inhibitor of metalloproteinase-1 expression in cultured human senescent fibroblasts. Chin Med J (Engl) 119 13 (2006) 1094-1102
21. Chen T.H., Wang J.F., Chan P., and Lee H.M. Angiotensin II stimulates hypoxia-inducible factor 1alpha accumulation in glomerular mesangial cells. Ann N Y Acad Sci 1042 (2005) 286-293
22. Sanchez-Lopez E., Lopez A.F., Esteban V., Yague S., Egido J., Ruiz-Ortega M., et al. Angiotensin II regulates vascular endothelial growth factor via hypoxia-inducible factor-1alpha induction and redox mechanisms in the kidney. Antioxid Redox Signal 7 9-10 (2005) 1275-1284
23. Hii S.I., Nicol D.L., Gotley D.C., Thompson L.C., Green M.K., and Jonsson J.R. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 77 6 (1998) 880-883
24. Volpert O.V., Ward W.F., Lingen M.W., Chesler L., Solt D.B., Johnson M.D., et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98 3 (1996) 671-679
25. Marsigliante S., Resta L., Muscella A., Vinson G.P., Marzullo A., and Storelli C. AT1 angiotensin II receptor subtype in the human larynx and squamous laryngeal carcinoma. Cancer Lett 110 1-2 (1996) 19-27
26. Takeda H., and Kondo S. Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am J Pathol 158 5 (2001) 1633-1637
27. Koh W.P., Yuan J.M., Van Den Berg D., Lee H.P., and Yu M.C. Polymorphisms in angiotensin II type 1 receptor and angiotensin I-converting enzyme genes and breast cancer risk among Chinese women in Singapore. Carcinogenesis 26 2 (2005) 459-464
28. Yuan J.M., Koh W.P., Sun C.L., Lee H.P., and Yu M.C. Green tea intake, ACE gene polymorphism and breast cancer risk among Chinese women in Singapore. Carcinogenesis 26 8 (2005) 1389-1394
29. Koh W.P., Yuan J.M., Sun C.L., van den Berg D., Seow A., Lee H.P., et al. Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore. Cancer Res 63 3 (2003) 573-578
30. Lindner D.J., and Borden E.C. Synergistic antitumor effects of a combination of interferon and tamoxifen on estrogen receptor-positive and receptor-negative human tumor cell lines in vivo and in vitro. J Interferon Cytokine Res 17 11 (1997) 681-693
31. Tahmasebi M., Barker S., Puddefoot J.R., and Vinson G.P. Localisation of renin-angiotensin system (RAS) components in breast. Br J Cancer 95 1 (2006) 67-74
32. Mack F.A., Rathmell W.K., Arsham A.M., Gnarra J., Keith B., and Simon M.C. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell 3 1 (2003) 75-88
33. Talks K.L., Turley H., Gatter K.C., Maxwell P.H., Pugh C.W., Ratcliffe P.J., et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157 2 (2000) 411-421
34. Giatromanolaki A., Sivridis E., Fiska A., and Koukourakis M.I. Hypoxia-inducible factor-2 alpha (HIF-2 alpha) induces angiogenesis in breast carcinomas. Appl Immunohistochem Mol Morphol 14 1 (2006) 78-82
35. Leek R.D., Talks K.L., Pezzella F., Turley H., Campo L., Brown N.S., et al. Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in human breast cancer. Cancer Res 62 5 (2002) 1326-1329
36. Yoshiji H., Harris S.R., Raso E., Gomez D.E., Lindsay C.K., Shibuya M., et al. Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int J Cancer 75 1 (1998) 81-87
37. Yamada E., Tobe T., Yamada H., Okamoto N., Zack D.J., Werb Z., et al. TIMP-1 promotes VEGF-induced neovascularization in the retina. Histol Histopathol 16 1 (2001) 87-97
38. Chen X., Wang J., Zhou F., Wang X., and Feng Z. STAT proteins mediate angiotensin II-induced production of TIMP-1 in human proximal tubular epithelial cells. Kidney Int 64 2 (2003) 459-467
39. Yoshiji H., Kuriyama S., and Fukui H. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol 23 6 (2002) 348-356
40. Yoshiji H., Kuriyama S., Kawata M., Yoshii J., Ikenaka Y., Noguchi R., et al. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 7 4 (2001) 1073-1078
41. Lindberg H., Nielsen D., Jensen B.V., Eriksen J., and Skovsgaard T. Angiotensin converting enzyme inhibitors for cancer treatment?. Acta Oncol 43 2 (2004) 142-152
42. Muramatsu M., Katada J., Hayashi I., and Majima M. Chymase as a proangiogenic factor. A possible involvement of chymase-angiotensin-dependent pathway in the hamster sponge angiogenesis model. J Biol Chem 275 8 (2000) 5545-5552